Detection of the tumour GZMB marker by flow cytometry and immunohistochemistry methods, respectively, showed a significant upregulation of GZMB expression in the MCT4i group (Figure 8D,E), indicating that inhibiting SLC16A3 could effectively enhance the cytotoxic ability of immune cells. This evidence concerns the gene SLC16A3 and neoplasm.